RecruitingPhase 3NCT04656184

A Trial Comparing the Efficacy and Safety of Anakinra Versus Intravenous Immunoglobulin (IVIG) Retreatment, in Patients With Kawasaki Disease Who Failed to Respond to Initial Standard IVIG Treatment

Studying Kawasaki disease

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Assistance Publique - Hôpitaux de Paris
Intervention
ANAKINRA(drug)
Enrollment
84 enrolled
Eligibility
17 years · All sexes
Timeline
2023 – 2027

Study locations (1)

Collaborators

Swedish Orphan Biovitrum

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04656184 on ClinicalTrials.gov

Other trials for Kawasaki disease

Additional recruiting or active studies for the same condition.

See all trials for Kawasaki disease →

← Back to all trials